Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.85 CHF | +5.28% | +8.48% | +21.39% |
05-03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
04-09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.39% | 570M | |
+24.67% | 46.71B | |
+48.83% | 41.8B | |
-1.05% | 41.52B | |
-5.86% | 29.55B | |
+10.86% | 25.78B | |
-20.48% | 19.26B | |
+2.40% | 12.14B | |
-2.54% | 12.08B | |
+28.38% | 11.98B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica Signs Evaluation License, Option Deal With Korea's iNtRON